Clal Biotech and partners file to raise $100m Nasdaq SPAC globes.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globes.co.il Daily Mail and Mail on Sunday newspapers.
Israeli Biotech Startup SpliSense Raises $28M For Cystic Fibrosis Therapeutics
Israeli biotech startup SpliSense, a pre-clinical developer of mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, has announced the closure of a $28.5 million Series B funding round with investors that include Orbimed, the Israel Biotech Fund, Biotel Limited, Integra Holdings, a major shareholder, and the US Cystic Fibrosis Foundation.
Founded in 2016, SpliSense created a platform that harnesses Anti Sense Oligonucleotides (ASO), small pieces of DNA or RNA that can bind to specific molecules of RNA, for the treatment of genetic diseases such as CF, a genetic disease that leads to respiratory infections and disabilities. CF is caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene, leading to dysfunctional CFTR proteins.
/PRNewswire/ SpliSense, a biopharmaceutical company developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary.
Cystic fibrosis treatment co Splisense raises $28.5m
The Jerusalem-based company is developing mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases.
Israeli biopharmaceutical cystic fibrosis treatment developer Splisense today announced that it has closed a $28.5 million Series B financing round with investments from Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation.
The Jerusalem-based company is developing mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases. SpliSense technology is based on the research of Hebrew University geneticist Prof. Batsheva Kerem, who was part of the research team that identified and cloned the CFTR gene. The technology was licensed from Yissum Technology Transfer Company of the Hebrew University of Jerusalem.
Published: May 13, 2021 By Mark Terry
closed on a $28.5 million Series B financing round. Participating in the round were
OrbiMed, Israel Biotech Fund, Integra Holdings, and the
The company plans to use the money to advance its pipeline, including SPL84-23, an Anti Sense Oligonucleotide (ASO) product designed to completely restore Cystic Fibrosis Transmembrane conductance Regulator (CFTR) channel function in patient-derived cell cultures. SpliSense is planning to launch a Phase I/IIa trial in 2022.
Cystic fibrosis (CF) is caused by mutations in the CFTR gene, which codes for the CFTR protein, a chloride channel expressed in many systems, particularly in the lungs. CF can be life-threatening. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. When the CFTR protein doesn’t work correctly, it can’t move chloride, a component of salt, to the cell surface. Because of the lack of chloride, water is not attracted to the cell